Prognostic and predictive role of ESR1 status for postmenopausal patients with endocrine-responsive early breast cancer in the Danish cohort of the BIG 1-98 trial
| Autor: | Julie Aldridge, Katrine L Henriksen, Meredith M. Regan, Henning T. Mouridsen, Richard D. Gelber, Karen N. Price, Birgitte Bruun Rasmussen, K. V. Nielsen, Anne E. Lykkesfeldt, Bent Ejlertsen, Sven Müller, Giuseppe Viale |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Adult
Oncology medicine.medical_specialty Antineoplastic Agents Hormonal medicine.drug_class Denmark Estrogen receptor Breast Neoplasms Cohort Studies Breast cancer Predictive Value of Tests Internal medicine Progesterone receptor Biomarkers Tumor medicine Humans skin and connective tissue diseases Aged Neoplasm Staging Randomized Controlled Trials as Topic Aged 80 and over Gynecology Aromatase inhibitor business.industry Letrozole Carcinoma Estrogen Receptor alpha Original Articles Hematology Middle Aged Prognosis medicine.disease Postmenopause body regions Treatment Outcome Cohort Female business Estrogen receptor alpha Tamoxifen medicine.drug |
| Zdroj: | Annals of Oncology. 23:1138-1144 |
| ISSN: | 0923-7534 |
| DOI: | 10.1093/annonc/mdr438 |
| Popis: | Estrogen Receptor 1 (ESR1) aberrations may be associated with expression of estrogen receptor (ER) or progesterone receptor (PgR), human epidermal growth factor receptor-2 (HER2) or Ki-67 labeling index and prognosis.ESR1 was assessed in 1129 (81%) of 1396 postmenopausal Danish women with early breast cancer randomly assigned to receive 5 years of letrozole, tamoxifen or a sequence of these agents in the Breast International Group 1-98 trial and who had ER ≥ 1% after central review.By FISH, 13.6% of patients had an ESR1-to-Centromere-6 (CEN-6) ratio ≥ 2 (amplified), and 4.2% had ESR1-to-CEN-6 ratio0.8 (deleted). Deletion of ESR1 was associated with significantly lower levels of ER (P0.0001) and PgR (P = 0.02) and more frequent HER2 amplification. ESR1 deletion or amplification was associated with higher-Ki-67 than ESR1-normal tumors. Overall, there was no evidence of heterogeneity of disease-free survival (DFS) or in treatment effect according to ESR1 status. However, significant differences in DFS were observed for subsets based on a combination of ESR1 and HER2 status (P = 0.02).ESR1 aberrations were associated with HER2 status, Ki-67 labeling index and ER and PgR levels. When combined with HER2, ESR1 may be prognostic but should not be used for endocrine treatment selection in postmenopausal women with endocrine-responsive early breast cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|